Advertisement

Topics

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

20:01 EDT 21 Aug 2017 | Cancer Connect

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express […]

The post The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia appeared first on .

Original Article: The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

NEXT ARTICLE

More From BioPortfolio on "The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...